Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:MREO NASDAQ:PRAX NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$31.20-3.3%$30.14$23.23▼$42.29$1.04B0.64396,663 shs219,382 shsMREOMereo BioPharma Group$1.77-0.6%$2.46$1.57▼$5.02$283.02M0.461.35 million shs2.37 million shsPRAXPraxis Precision Medicines$53.85-2.0%$43.38$26.70▼$91.83$1.12B2.6370,149 shs394,544 shsPROKProKidney$3.15-10.5%$1.33$0.46▼$7.13$1.03B1.263.61 million shs6.55 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-3.29%-4.06%+5.41%+15.51%-2.32%MREOMereo BioPharma Group-0.56%+9.94%-38.33%-23.04%-54.50%PRAXPraxis Precision Medicines-1.98%+6.55%+25.32%+59.37%-2.29%PROKProKidney-10.51%-30.62%+352.39%+298.28%+36.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.4139 of 5 stars3.42.00.03.03.50.82.5MREOMereo BioPharma Group1.5881 of 5 stars3.61.00.00.01.51.70.0PRAXPraxis Precision Medicines2.454 of 5 stars4.41.00.00.02.11.70.0PROKProKidney3.402 of 5 stars3.24.00.00.03.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7540.22% UpsideMREOMereo BioPharma Group 3.20Buy$7.20306.78% UpsidePRAXPraxis Precision Medicines 2.78Moderate Buy$94.1174.77% UpsidePROKProKidney 2.40Hold$6.2598.41% UpsideCurrent Analyst Ratings BreakdownLatest MREO, PRAX, PROK, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$105.007/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $7.007/10/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$7.00 ➝ $5.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $9.007/8/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.006/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.006/12/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/2/2025PRAXPraxis Precision MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform$97.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.59$11.95 per share2.61$7.10 per share4.39MREOMereo BioPharma Group$10M28.14N/AN/A$0.39 per share4.54PRAXPraxis Precision Medicines$8.55M128.30N/AN/A$23.90 per share2.25PROKProKidney$80K11,525.06N/AN/A($3.41) per share-0.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.2225.575.18N/A6.61%99.08%15.14%8/6/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest MREO, PRAX, PROK, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COLLCollegium Pharmaceutical$1.88N/AN/AN/A$182.26 millionN/A8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01N/AN/AN/AN/AN/A8/12/2025Q2 2025PRAXPraxis Precision Medicines-$3.40N/AN/AN/A$0.16 millionN/A8/8/2025Q2 2025PROKProKidney-$0.14N/AN/AN/AN/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/2/2025Q1 2025PRAXPraxis Precision Medicines-$3.20-$3.29-$0.09-$3.29$0.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.301.081.01MREOMereo BioPharma GroupN/A8.928.92PRAXPraxis Precision MedicinesN/A8.448.44PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AMREOMereo BioPharma Group62.83%PRAXPraxis Precision Medicines67.84%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%MREOMereo BioPharma Group5.50%PRAXPraxis Precision Medicines2.70%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionablePRAXPraxis Precision Medicines11020.37 million19.82 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableMREO, PRAX, PROK, and COLL HeadlinesRecent News About These CompaniesProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?July 18 at 12:35 PM | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives $5.67 Average Price Target from AnalystsJuly 18 at 2:23 AM | americanbankingnews.comPROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?July 17 at 1:01 PM | zacks.comBest Momentum Stocks to Buy for July 17thJuly 17 at 11:01 AM | zacks.comNew Strong Buy Stocks for July 17thJuly 17 at 6:40 AM | zacks.comProKidney gains pivotal therapy advancement step with FDAJuly 17 at 6:15 AM | journalnow.comJProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?July 16 at 1:01 PM | zacks.comProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst UpgradeJuly 16 at 2:18 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Up on Analyst UpgradeJuly 16 at 2:27 AM | americanbankingnews.comPromising clinical trial results give ProKidney share price major boostJuly 15, 2025 | journalnow.comJProKidney stock soars after FDA confirms accelerated approval pathwayJuly 15, 2025 | in.investing.comProKidney Shares Dip Following FDA Agreement on Rilparencel Approval StrategyJuly 15, 2025 | msn.comProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug TrialJuly 15, 2025 | marketwatch.comProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15, 2025 | finance.yahoo.comProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst UpgradeJuly 15, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from BrokeragesJuly 15, 2025 | marketbeat.comProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and DiabetesJuly 15, 2025 | quiverquant.comQProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15, 2025 | globenewswire.comProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst UpgradeJuly 14, 2025 | marketbeat.comGuggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00July 14, 2025 | marketbeat.comPromising clincial trial results give ProKidney share price major boostJuly 14, 2025 | greensboro.comGNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseConagra at Rock Bottom: 7% Yield & Turnaround PoisedBy Thomas Hughes | July 13, 2025View Conagra at Rock Bottom: 7% Yield & Turnaround PoisedMREO, PRAX, PROK, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$31.20 -1.06 (-3.29%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$31.20 0.00 (-0.02%) As of 07/18/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Mereo BioPharma Group NASDAQ:MREO$1.77 -0.01 (-0.56%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.75 -0.02 (-1.13%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Praxis Precision Medicines NASDAQ:PRAX$53.85 -1.09 (-1.98%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$53.86 +0.00 (+0.01%) As of 07/18/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.ProKidney NASDAQ:PROK$3.15 -0.37 (-10.51%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.20 +0.04 (+1.43%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
